Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Consumers should be skeptical of any over-the-counter product marketed as a GLP-1 supplement that suggests it can act like a prescription drug, replace a GLP-1 medication or treat a disease such as obesity, says Jeff Ventura, a spokesperson for the Council for Responsible Nutrition, which represents the dietary supplement industry
The growing trend of lifestyle modifications and preventive healthcare initiatives has further encouraged early adoption of these medications, solidifying their role in long-term metabolic disease management
Greenberg recently published a paper indicating that another hormone, when combined with GLP-1 agonist drugs, may reduce rates of gastric emptying even further
ISBN 978-0-387-78518-9
Early outcomes depend on dosage, eating habits, and exercise
Our article also includes: Sandoz's patenting activity across key technology areas Key firms behind Sandoz's patent filings: PRFER & PARTNER mbB, Luedeka Neely, P.C., Griffith Hack, KAWAGUTI & PARTNERS, Lavery, and more Read more: #ParolaNEWS #Patents #Innovations #Sandoz #EliLilly #Tirzepatide #GLP1 #PatentLandscape #Biopharma #PharmaceuticalInnovation #GenericDrugs #IPStrategy #PatentCliff To view or add a comment, sign in As the GLP-1 market continues to grow, patent strategy is becoming an increasingly important driver of competition and market entry
